Pharma
Milner Institute announces launch of Bio-spark 2025
Early career scientists interested in entrepreneurship can apply for the 2025-26 Bio-spark programme until 13 October. ...
DJR Care comes to The EpiCentre
DJR Care, a facilitator to the healthcare sector, has opened an office at The EpiCentre in Haverhill, focused on enhancing the efficiency and effectiveness of healthcare and residential care services through its own “DJR Care Model”. ...
Free Virtual Workshop: How to Use the Docking Software GOLD to Perform Virtual Screening Simulations
In drug discovery, virtual screening (VS) is a widely used computational technique for identifying hits, optimizing leads, and performing scaffold hopping by searching libraries of small molecules. It can significantly reduce research time and cost through two primary approaches: struct...
Free Virtual Workshop: How to Use Particle Informatics Tools to Connect Crystal Structure to Particle Behaviour
In silico design methods are gaining popularity in the formulated products industry to predict manufacturing and processing bottlenecks. The CSD-Particle informatics tools use the Cambridge Structural Database (CSD) to reveal the surface chemistry and topology of crystal facets. ...
Nxera Pharma notes positive topline results from its Phase 2 clinical study in adults with schizophrenia
Tokyo, Japan and Cambridge, UK - Nxera Pharma Co., Ltd. – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc., that NBI-1117568 (NBI-‘568) has delivered positive topline results from its Phase 2 clinical study in adults wit...
Nxera Pharma to receive US$35 Million from Neurocrine Biosciences upon positive phase 2 data for partnered Schizophrenia candidate NBI-1117568
Tokyo, Japan and Cambridge, UK - Nxera Pharma Co., Ltd. - formerly known as Sosei Group or Sosei Heptares – announces it will receive a US$35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults wi...
Nxera Pharma receives approval of QUVIVIQ (daridorexant) in Japan for the treatment of insomnia
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints Plans to make QUVIVIQ available as soon as possible to insomnia patients in Ja...
Nxera Pharma appoints experienced commercial R&D executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Tokyo, Japan and Cambridge, UK – Nxera Pharma Co., Ltd. – formerly known as Sosei Group or Sosei Heptares – announces the appointment of Dr. Makoto Sugita, M.D., Ph.D., MBA, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief M...
AstraZeneca unveils The Hub, a new amenities centre, on Cambridge Biomedical Campus
AstraZeneca has today officially opened The Hub in Cambridge, a purposely designed amenities centre, where employees and the local community can collaborate, socialise and unwind. Located at the heart of the Cambridge Biomedical Campus (CBC), The Hub offers a wide range of facilities ...
Brockbank Plaut Consulting forms strategic alliance with Arttteo Software Development
Brockbank Plaut Consulting Limited has recently formed a strategic alliance with Arttteo Software Development. Arttteo, based in Georgia (Europe), Arttteo has built a significant talent pool; and has developed specialist expertise in Augmented Reality and Virtual Reality (AR/VR), in w...